[1. Fuks AG, Vaisman M, Buescu. Thyroid dysfunction and cardiological management in patients receiving amiodarone. Arquivos Brasileiros de Cardiologia. 2004;82(6):528-532.]Search in Google Scholar
[2. Siddoway LA. Amiodarone: guidelines for use and monitoring. American family physician. 2003;68(11):2189-96.]Search in Google Scholar
[3. Podrid PJ. Amiodarone reevaluation of an old drug. Ann. Intern. Med. 1995;122:689-700.10.7326/0003-4819-122-9-199505010-00008]Search in Google Scholar
[4. Beddows S, Page S, Taylor A, et al. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes. Biochem. Pharmacol. 1989;38:4397-4403.]Search in Google Scholar
[5. Basaria S, Cooper D. Amiodarone and the thyroid. Am. J. Med. 2005;118:706-714.10.1016/j.amjmed.2004.11.028]Search in Google Scholar
[6. Padmanabhan H. Amiodarone and thyroid disfunction. South Med. J. A. 2010;103(9):922-930.]Search in Google Scholar
[7. Trip M, Wiersinga W, Plomp T. Incidence, predictability and pathogenesis of amiodarone - induced thyrotoxicosis and hypothyroidism. Am. J. Med. 1991;91:507-511.10.1016/0002-9343(91)90187-3]Search in Google Scholar
[8. Hofman A, Nawara C, Ofl uoglu S, et al. Incidence and predictability of amiodaroneinduced thyrotoxicosis and hypothyroidism. Wien Klin Wochenschr. 2008;120(15-16):493-8.10.1007/s00508-008-1017-218820854]Search in Google Scholar
[9. Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res. 1987;26:158.10.1159/0001806962885251]Search in Google Scholar
[10. Martino E, Bartalena L, Bogazzi F, et al. The effects of amiodarone on the thyroid. Endocr. Rev. 2001;22:240-254.]Search in Google Scholar
[11. Bogazzi F, Martino E, Dell Unto E et al. Thyroid color fl ow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced tyrotoxicosis. J Endocrinol Invest. 2003;26(7):635-640.10.1007/BF0334702114594114]Search in Google Scholar
[12. Bogazzi F, Bartalena L, Tomisi L et al. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive tyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab. 2007;92:556-562.10.1210/jc.2006-205917148557]Search in Google Scholar
[13. Piga M, Serra A, Boi F et al. Amiodarone- induced thyrotoxicosis. A review. Minerva Endocrinol. 2008;33(3):213-228.]Search in Google Scholar
[14. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone. Heart Rhythm. 2007;4(9):1250-1259.10.1016/j.hrthm.2007.07.02017765636]Search in Google Scholar
[15. Franklyn JA. Amiodarone and thyroid hormone action. Clin. Endocinol. 1985;22:257.]Search in Google Scholar
[16. Gopalan M. Thyroid dysfunction induced by amiodarone therapy. Updated: Jul 2, 2009. Workup http://emedicine.medscape.com/article/129033-workup#a0723.]Search in Google Scholar
[17. Sidhu J, Jenkins D. Men are at increased risk of amiodarone-induced thyrotoxicosis in the UK. QJM. 2003;12:949-950.10.1093/qjmed/hcg15814631062]Search in Google Scholar
[18. Aleksic Z, Aleksic A. Incidence of amiodarone-induced thyroid disfunction and predictive factors for theier occurrence. Med Pregl. 2011;64(11-12): 533-538.10.2298/MPNS1112533A]Search in Google Scholar
[19. Liang YL, Huang SM, Peng SL, et al. Amiodarone-induced thyrotoxicosis in a patient with autonomously functioning nodular goiter. Ann Pharmacother. 2009;43(1):134-8.10.1345/aph.1L34719109209]Search in Google Scholar
[20. Tomisti L, Dell’Unto E, Brogioni S, et al. Amiodarone induced thyrotoxicosis in patients with multinodular goiter: type 1 or type 2 AIT? Endocr Abst. 2010;22:765.]Search in Google Scholar
[21. Davis AB, Orlander PR. Goiter, Toxic Nodular. Updated: Apr 26, 2010. Available from: http://emedicine.medscape.com/article/120497-overview.]Search in Google Scholar
[22. Bogazzi F, Bartalena L, Dell’Unto E, et al. Proportion of type 1 and type 2 Amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol. 2007;67:533-537.10.1111/j.1365-2265.2007.02920.x17561980]Search in Google Scholar
[23. Zosin I, Balas M. Amiodarone induced thyroid disfunction in an iodine replete area: epidemiological and clinical data. Polish Jurnal Endoc. 2012;63(1):2-9.]Search in Google Scholar
[24. Binz K, Burger A, Vallotton MB. Amiodarone and thyroid function: clinical implications. Schweiz Med Wochenschr. 1998;128:1051-1058.]Search in Google Scholar
[25. Fiorini A. Monitoring thyroid function status in elderly patients on amiodarone. Malta Med J. 2006;18-24.]Search in Google Scholar
[26. Kun I, Szántó Z, Balázs J, et al. Detection of Iodine Defi ciency Disorders (Goiter and Hypothyroidism) in School-Children Living in Endemic Mountainous Regions, After the Implementation of Universal Salt Iodization. Hot Topics in Endocrine and Endocrine-Related Diseases, Dr. Monica Fedele (Ed.), ISBN: 978-953-51-1080-4, InTech, DOI: 10.5772/54188.10.5772/54188]Search in Google Scholar
[27. Simescu M, Dumitriu L, Kun I, et al. Urinary Iodine Levels in Schoolchildren and Pregnant Women After the Legislative Changes in the Salt Iodization. Acta Endocrinologica New series. 2006;2(1):33-44.10.4183/aeb.2006.33]Search in Google Scholar
[28. Toma A, Sava M, Delia C, et al. Universal Salt Iodization Effects on Endemic Goiter in Arges County, Romania. Acta Endocrinologica (Bucharest), New series. 2005;1(2):167-180.10.4183/aeb.2005.167]Search in Google Scholar